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Abstract
In December 2019, a newly discovered SARS-CoV-2 virus emerged from China and prop-
agated worldwide as a pandemic, resulting in about 35% mortality. In the absence of
preventive medicine or a ready to use vaccine, mathematical models can provide useful
scientific insights about transmission patterns and targets for drug development. In this
study, we propose a within-host mathematical model of SARS-CoV-2 infection consid-
ering innate and adaptive immune responses. We analyze the equilibrium points of the
proposed model and obtain an expression of the basic reproduction number. We then
numerically show the existence of a transcritical bifurcation. The proposed model is cal-
ibrated to real viral load data and using the estimated parameters, we perform global
sensitivity analysis with respect to the peak of viral load. Finally, we study the efficacy
of antiviral drugs and vaccination on the dynamics of SARS-CoV-2 infection. Our results
suggest that blocking virus production from infected cells is more effective than reducing
the infection rate in terms of decrease in viral load. Vaccination is also found useful but
during the vaccine development phase, blocking virus production from infected cells can
be targeted for antiviral drug development.
Keywords: SARS-CoV-2, Immune response, Model calibration, Numerical simulation,
Treatments.
1. Introduction
Coronaviruses are a large group of viruses that have the potential to transmit between
hosts. These are enveloped in positive-sense, non-segmented RNA viruses belonging to
the Coronaviridae family (Nidovirales order) and widely distributed in humans and other
mammals [1]. The virus is responsible for a range of symptoms including fever, cough,
and shortness of breath [1]. Some patients have reported radiographic changes in their
ground-glass lungs, healthy or lower than average white blood cell lymphocyte, and
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platelet counts; hypoxaemia; and deranged liver and renal function. Since first discovery
and identification of coronavirus in 1965, three significant outbreaks occurred, caused by
emerging, highly pathogenic coronaviruses, namely the 2003 outbreak of ”Severe Acute
Respiratory Syndrome” (SARS) in mainland China [2, 3], the 2012 outbreak of ”Mid-
dle East Respiratory Syndrome” (MERS) in Saudi Arabia [4, 5], and the 2015 outbreak
of MERS in South Korea [6, 7]. These outbreaks resulted in SARS and MERS cases
confirmed by more than 8000 and 2200, respectively [8]. A new, genetically similar coro-
navirus to the viruses that cause SARS and MERS causes the coronavirus disease 2019
(COVID-19). The virus is named SARS-CoV-2. Despite a relatively lower case fatality
rate compared to SARS and MERS, the COVID-19 spreads rapidly and infects more peo-
ple than the SARS and MERS. Despite strict intervention measures implemented in the
region where the COVID-19 was originated, the infection spread locally and elsewhere
very rapidly. COVID-19 has been declared a pandemic by the World Health Organiza-
tion in January 2020. Since its first isolation in Wuhan, China in December 2019, it has
caused outbreak with more than 6.2 million confirmed infections and above 370 thou-
sand reported deaths worldwide as of 31 May 2020. The affected countries around the
globe are fighting the virus by implementing social distancing and isolation strategies.
Unfortunately, the COVID-19 has neither a preventive medicine nor a ready to use vac-
cine. Multiple approaches are adopted in the development of Coronavirus vaccines; most
of these targets the surface-exposed spike (S) glycoprotein or S protein as the primary
inducer of neutralizing antibodies [9, 10]. In fact, either monoclonal antibody or vaccine
approaches have failed to neutralize and protect from previous coronavirus infections
[11]. Therefore, individual behaviour (e.g. early self-isolation and social distancing), as
well as preventive measures such as hand washing, covering when coughing, are critical
to control the spread of COVID-19 [12]. However, researchers have been putting more
effort into finding a solution to this pandemic situation [13, 14, 15].
In addition to medical and biological research, theoretical studies based on math-
ematical models may also play an important role throughout this anti-epidemic fight
in understanding the epidemic character traits of the outbreak, in having to decide on
the measures to reduce the spread and in understanding within-host patterns of virus
transmission. While there are many mathematical models developed at an epidemiolog-
ical level for COVID-19 [16, 17, 18, 19], there are very few within-host level studies to
understand SARS-CoV-2 replication cycle and its interactions with the innate and adap-
tive immune responses [20, 12]. In these few previous studies, authors studied target
cell models and target cell models with eclipse phase. Therefore, a detailed study with
immune responses is necessary for the understanding of SARS-CoV-2 spread inside the
human body. The human immune system is comprised of innate and adaptive immune
responses. While the adaptive immune system is both fast and effective at targeting
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invasions by previously encountered pathogens, its role in host defence in the first days
of a new infection is secondary to that of the innate immune system.
Motivated by this discussion, we aim to develop a within-host mathematical model of
SARS-CoV-2 infection considering human immune responses. This model can be used as
a basis for understanding characterized patterns of disease severity in humans. Moreover,
we intend to use real viral load data from COVID-19 positive patients to calibrate the
proposed model so that the parameters are realistic for further inference. The main
goal is to compare the efficacy of various antiviral drugs and identify the most beneficial
target.
The rest of the paper is organized as follows: in Section 2, we formulate the com-
partmental model of within human SARS-CoV-2 transmission; the equilibrium points
of the proposed model are analyzed and the basic reproduction number is obtained in
Section 3; viral load time series, transcritical bifurcation, fitting model to real data and
global sensitivity analysis are presented in Section 4; in Section 5, we study the efficacy
of antiviral drugs and vaccination; finally, the obtained results are discussed in Section
6.
2. The mathematical model
A deterministic ordinary differential equation model describing cell–virus–immune
response interaction dynamics of SARS-CoV-2 infection is being formulated. Time-
dependent state variables are taken to represent the compartments. A general mathe-
matical model for the underlying dynamics of virus-host cell interaction has been studied
in this context [20, 12]. However, the basic principles that underlay models of virus
dynamics are as follows: Healthy uninfected cells, H(t), are infected when they meet
free viruses, V (t). Infected cells, I(t), produce new virus particles that leave the cell
and find other susceptible target cells. Whenever a human is infected with SARS-CoV-
2, his innate and adaptive immune responses work together to neutralize the threat of
SARS-CoV-2 infection [21, 22, 15]. The innate immune response works non-specifically
and immediately after the viral attack. Cells and proteins of the innate immune system
are ever-present in a healthy host and can respond to invading pathogens within the first
minutes and hours of infection [23]. This system is of great importance in the sense that
it is preventing the establishment of new infections during the activation time of the
adaptive immune system. It is believed that Cytokines are an essential component of the
immune system [24]. They are a family of small soluble proteins secreted by different
cells. They can be loosely classified into one of four families: the haematopoietins, the
immunoglobin superfamily, the tumour necrosis factor family and the interferons (IFN).
Cytokines modulate the balance between innate and adaptive immune responses. The
IFNs are perhaps the most critical cytokines in the initial innate response to viral in-
3
fection. They are classified into two types: IFN-α (a family of related proteins) and
the single protein IFN-β together form type I; IFN-γ is the sole and unrelated type II
IFN. IFN-α and IFN-β are secreted by cells in response to viral infection and promote
an antiviral response in otherwise susceptible cells. Cytokines X(t) is vital in inhibiting
viral replication and modulating downstream effects of the immune response. Specific
cytokines also activate natural killer (NK) cells, which play an essential role in killing
virus-infected cells. While modeling, a simplifying assumption that the reduction in
infected cells through NK cells is proportional to the circulating cytokines. This assump-
tion can be justified through the quasi-steady-state approximation of NK cells. However,
Against the inhibiting mechanism of cytokines, the viruses often target the JaK/STAT
pathway to decrease the production of IFNs. This mechanism, known as immunosupres-
sion, is observed for SARS-CoV-2 [25]. The functional form of a decrease in the cytokine
production rate is assumed to be k2I
1+γV
.
Meanwhile, cytokines also activate the adaptive immune system, mainly the cyto-
toxic T-lymphocytes. T-cells subsequently activate B-lymphocytes to produce antibody
against the virus. B-cells mainly secrete IgM and IgG antibodies that are released in the
blood and lymph fluid, where they specifically recognize and neutralize the SARS-CoV-2
viral particles [24, 21]. Meanwhile, antibody levels A(t) are increasing with the aim of
halting infection (and in future providing protection against a subsequent infection). A
schematic flow diagram of the model is depicted in Fig. 1.
Finally, the cell–virus–immune response interaction dynamics of SARS-CoV-2 infec-
tion are governed by the following system of differential equations:
dH
dt
= Π− βHV − µ1H,
dI
dt
= βHV − p1CI − µ2I,
dV
dt
= k1I − p2CV − p3AV − µ3V,
dC
dt
=
k2I
1 + γV
− µ4C, (2.1)
dT
dt
= λ1TC − µ5T,
dB
dt
= λ2BT − µ6B,
dA
dt
= H(t− τ)ηB − p4AV − µ7A.
The time delay τ introduced through the Heaviside step function [26], is the time
period that is required for the first production of antibodies after the T-lymphocytes
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Figure 1: Schematic diagram of the proposed model.
and B-lymphocytes interact. This delay is biologically significant since the production of
antibodies after the virions have associated with the B-lymphocytes is a complex process
involving multiple steps. The B-cells have to undergo differentiations before they can be
transformed into the plasma cells capable of producing antibodies [27]. The Heaviside
step function H(t) is defined as follows,
H(t− τ) = 1, if t > τ
= 0, if t < τ
The model 2.1 has initial conditions given by: H(0) = H0 ≥ 0, I(0) = I0 ≥ 0,
V (0) = V0 ≥ 0, C(0) = C0 ≥ 0, T (0) = T0 ≥ 0, B(0) = B0 ≥ 0, and A(0) = A0 ≥ 0.
3. Equilibria and Basic reproduction number
There are four type of equilibia of the system (2.1), namely,
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Table 1: Parameters used in model 2.1
Parameter Symbol value/Range Reference
Production rate of healthy cells Π 4 × 103 [28]
Rate at which healthy cells are
converted to infected cells
β (5 – 561) × 10−9 [12]
Strength of immunosupresion γ 0.5 Assumed
Rate at which cytokines destroy
infected cells
p1 0.001 [29]
Rate at which viral particles are
neutralized by cytokines
p2 (0 – 1) Estimated
Rate at which viral particles are
neutralized by antibodies
p3 (0 – 1) Estimated
Rate at which virus neutralize an-
tibodies
p4 3 × 10
−7 [28]
Production rate of virus from in-
fected cells
k1 (8.2 – 525) [12]
Production rate of cytokines k2 (0 – 10) Assumed
Activation rate of T cells λ1 0.1 [24]
Activation rate of B cells λ2 0.01 [24]
Rate at which antibodies are pro-
duced
η (0 - 1) [27]
Natural death rate of Healthy
cells and protected cells
µ1 0.14 [24]
Natural death rate of infected
cells
µ2 (0 – 1) Assumed
Clearance rate of virus µ3 (0 – 1) Estimated
Natural death rate of cytokines µ4 0.7 Assumed
Natural death rate of T cells µ5 1 [24]
Natural death rate of B cells µ6 0.2 [28]
Natural death rate of antibodies µ7 0.07 [24]
Time delay for antibody produc-
tion
τ 7 – 14 [30]
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(a) The disease free equilibrium (DFE) given by E0 = (
Π
µ1
, 0, 0, 0, 0, 0, 0).
(b) The virus persistence equilibrium in the absence of immune responses, given by
E1 = (H1, I1, V1, 0, 0, 0, 0), where H1 =
Π
µ1R0
, I1 =
µ1µ3
βk1
(R0− 1) and V1 =
µ1
β
(R0− 1) with
R0 =
Πβk1
µ1µ2µ3
. Clearly, this equilibrium exists only when R0 > 1.
(c) The virus persistence equilibrium in the absence of adaptive immune responses,
given by E1 = (H2, I2, V2, C2, 0, 0, 0), where (assume, Q = βH2V2) H2 =
Π−Q
µ1
, I2 =
Q
µ2+p1C2
, V2 =
k1Q
(µ2+p1C2)(µ3+p2C2)
and C2 is given by the roots of the following cubic equation
p1p2µ4C
3
2 + (µ2µ4p2 + µ3µ4p1)C
2
2 + (µ2µ3µ4 + µ4γk1Q− k2p2Q)C2 − k2µ3Q = 0
. Note that, irrespective of the sign of the coefficient of C2, Descartes’ rule of sign ensure
existence of exactly one positive root.
(d) The all cells and virus co-existence equilibrium, given by E2 = (H3, I3, V3, c3, T3, B3, A3),
where (assume, Q = βH3V3) H3 =
Π−Q
µ1
, I3 =
λ1Q
λ1µ2+p1µ5
, V3 =
1
γ
[R1 − 1], C3 =
µ5
λ1
,
T3 =
µ2
λ2
, B3 =
A3
η
[p4V3 + µ7] and A3 =
1
p3V3
[R2 − 1], with R1 =
λ2
1
k2Q
µ4µ5(λ1µ2+p1µ5)
and
R2 =
γλ2
1
k1Q
(λ1µ2+p1µ5)(λ1µ3+p2µ5)(R1−1)
. It can be noted that this equilibrium exists only when
R1 > 1 and R2 > 1.
Theorem 3.1. The DFE E0 of the system (2.1) is locally asymptotically stable, if R0 < 1,
and unstable if R0 > 1, where
R0 =
Πβk1
µ1µ2µ3
. (3.1)
Proof. The Jacobian of the system (2.1) at E0 is given as
J(E0) =


−µ1 0 −
βΠ
µ1
0 0 0 0
0 −µ2
βΠ
µ1
0 0 0 0
0 k1 −µ3 0 0 0 0
0 k2 0 −µ4 0 0 0
0 0 0 0 −µ5 0 0
0 0 0 0 0 −µ6 0
0 0 0 0 0 H(t− τ)η −µ7


(3.2)
Clearly, −µ1, −µ4, −µ5, −µ6 and −µ7 are eigenvalues of this Jacobean matrix and
other two eigenvalues are given by the roots of the following equation
C(Λ) := Λ2 + a1Λ + a2 = 0
(3.3)
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where
a1 = µ2 + µ3
a2 = µ2µ3 (1− R1)
(3.4)
Therefore, for R0 < 1, the conditions for the Routh-Hurwitz criteria are satisfied and
hence DFE is locally asymptotically stable. Now if R0 > 1, then a2 < 0 and C(λ) = 0
will possess a positive real solution. Therefore the DFE will be unstable for R0 > 1.
Hence the proof follows.
The stability of the other three equilibrium points is complicated and does not lead to
biologically relevant stability conditions. Therefore, we explore model solutions, relevant
model dynamics, important parameters, agreement with real data through numerical
simulations.
4. Numerical Simulation
In this section, important properties of the proposed model are investigated numeri-
cally. Using different parameter settings, time series and threshold analysis is performed.
Moreover, the agreement of the model solution with real data is explored. Through out
this section the following set of initial conditions is used unless stated H(0) = 4 × 105,
I(0) = 3× 10−4, V (0) = 357, C = 0, T = 500, B = 100 and A = 0.
4.1. Time series and threshold analysis
We first study the time series of the viral load and antibody count. In Fig. 2, the viral
load and antibody are plotted. The viral load time series experiences a peak between
sixth and seven days post infection. However, as soon as the adaptive immune response is
activated (after τ = 7 days), a sharp decrease is observed in the viral load. On the other
hand, the antibody count starts to rise after 7 days post infection and shows saturated
type behaviour.
Further, we study the threshold for R0. It is observed that R0 = 1 acts as a critical
value for the persistence of virus particles. The virus particles converges to the DFE of
the model 2.1 for R0 < 1 and the viral load converges to a non-zero value as soon as
R0 crosses unity. This type of phenomenon is called forward bifurcation where the two
equilibrium points switches their stability at a critical value. The diagram is depicted in
Fig. 3. This also ensure that if we vary other parameters involved in the expression of
R0, the same type of phenomenon occurs. Thus, in turn parameters such as β and k1
can be reduced so as to reduce R0 below unity.
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Figure 2: Time evolution of (a) viral load (V ) and (b) antibody count (A) of the model 2.1. All the
parameters are taken from Table 1 except β = 2 × 10−8, µ2 = 0.65, µ3 = 0.9, p2 = 0.001, p3 = 0.05,
k1 = 500, k2 = 5, η = 0.05 and τ = 7.
4.2. Model validation using real data
SARS-CoV-2 viral load data are obtained from Wolfel et al. [31]. They studied
patients from a hospital in Munich, Germany. They reported Daily measurements of
viral load in sputum, pharyngeal swabs and stool for 9 patients. Among these patients,
there were two patients (namely, patient A and patient B) for whom the growth phase
of sputum data was captured. We therefore utilized these two datasets for our analysis.
The data was collected from Wolfel et al. [31] using a online software [32].
The solution curve of viral load (V (t)) is fitted to data using the built-in (MATLAB,
R2018a) simplex algorithm to minimize the sum of squares difference between simulated
indicators and data. We used the MATLAB function ‘fminsearchbnd’ to perform the
optimization. During the computation, 100 different starting points in parameter space
were chosen using Latin Hypercube Sampling to ensure consistency and uniqueness of
the parameter estimates. The fitting is displayed in Fig. 4(a) for patient A and in Fig.
4(b) for patient B. The fixed parameters are taken from Table 1 with µ2 = 0.65, k2 = 5
and η = 0.05. The initial conditions are taken as mentioned in the beginning of Section
4. We estimated five parameters directly related to viral load of a patient viz., β, k1, p2,
p3 and µ3. The estimated parameters for patient A are found to be β = 1.3281× 10
−6,
k1 = 498.56, p2 = 0.0011, p3 = 0.0546 and µ3 = 0.8001. Similarly, the estimates for
patient B are obtained as β = 6.1738× 10−7, k1 = 100.23, p2 = 0.0969, p3 = 0.0093 and
µ3 = 0.9527.
4.3. Sensitivity analysis
We performed global sensitivity analysis to identify most influential parameters with
respect to the maximum size (or alternatively, the peak of load) of virus particles (Vmax)
in 3 months time frame. Partial rank correlation coefficients (PRCCs) are calculated and
plotted in Fig. 5. Nonlinear and monotone relationship were observed for the parameters
with respect to Vmax, which is a prerequisite for performing PRCC analysis. Following
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Figure 3: Forward bifurcation diagram with respect to basic reproduction number. All the fixed param-
eters are taken from Table 1 with µ2 = 0.65, µ3 = 0.9, p2 = 0.001, p3 = 0.05, k1 = 500, k2 = 5, η = 0.05,
τ = 7 and 10−9 < β < 10−7,
Marino et. al [33], we calculate PRCCs for the parameters β, k1, k2, µ2, µ3, p2, p3, γ and
η. The base values for the parameters β, k1, p2, p3 and µ3 are taken as the average of
estimated parameters of patient A and patient B. The other base values are µ2 = 0.65,
k2 = 5, γ = 0.5 and η = 0.05. For each of the parameters, 500 Latin Hypercube Samples
were generated from the interval (0.5 × base value, 1.5 × base value).
It is observed that the parameters β, k1 and γ has significant positive correlations
with Vmax. This indicates that the production rate of virus particles from infected cells
will increase the chance of larger infection propagation. Besides, the infection rate and
the immiunosuppresion rate will increase the peak of viral load. On the other hand,
the natural death rate of infected cells and death rate of virus particles will have signifi-
cant negative correlation with Vmax. The production rate of cytokines is also negatively
correlated with Vmax.These results reinforces the fact that β and k1 are very crucial for
reduction of viral load.
5. Model with antiviral treatment
Antiviral drugs can be used to slow SARS-CoV-2 infection or block production of
virus particles. These drugs will necessarily save the lives of many severely ill patients
and will reduce the time spent in intensive care units for patients, vacating hospital beds.
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Figure 4: Fitting model solution to (a) patient A data and (b) patient B data.
Antiviral medications will, in turn, inhibit subsequent transmission that could happen if
the drugs were not given. However, to analyze the effect of antiviral treatment, we con-
sider drugs can block infection and/or production of virus particles. Many studies have
suggested various existing compounds for testing [15, 34, 35] as SARS-CoV-2 antiviral
drug, but World Health Organization (WHO) is focusing on the following four therapies:
an experimental antiviral compound called remdesivir; the malaria medications chloro-
quine and hydroxychloroquine; a combination of two HIV drugs, lopinavir and ritonavir;
and that same combination plus interferon-beta, an immune system messenger that can
help cripple viruses [36].
Following Zitzmann et al. [37], we incorporate antiviral drug treatment in the pro-
posed model (2.1). The modified system with antiviral treatment is given by
dH
dt
= Π− (1− ǫ1)βHV − µ1H,
dI
dt
= (1− ǫ1)βHV − p1CI − µ2I,
dV
dt
= (1− ǫ2)k1I − p2CV − p3AV − µ3V,
dC
dt
=
k2I
1 + γV
− µ4C, (5.1)
dT
dt
= λ1TC − µ5T,
dB
dt
= λ2BT − µ6B,
dA
dt
= H(t− τ)ηB − p4AV − µ7A.
From Fig. 6, it can be noted that increase in ǫ1 reduces the peak of viral load but the
duration of high viral load remains same. On the other hand, increase in ǫ2 significantly
reduce both peak of viral load and duration of high viral load. Thus, we conclude that
11
β k1 k2 µ2 µ3 p2 p3 γ η
-1
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
0.8
1
PR
CC
*
*
*
*
*
*
*
*
significant (p-value < 0.05)
Figure 5: Effect of uncertainty of the model (2.1) on the peak of viral load. Parameters with significant
PRCC indicated as ∗ (p-value < 0.05). The fixed parameters are taken from Table 1 with µ2 = 0.65,
k2 = 5, η = 0.05 and τ = 7.
blocking the virus production from infected cells is a more suitable target for antiviral
drug development.
Finally, we study the effect vaccination in the viral dynamics of SARS-CoV-2 in
humans. A vaccine is a biological preparation that provides active acquired immunity
to a particular infectious agent. Thus if an individual is vaccinated, there will be no
delay in the development of antibody. Therefore, the delay term τ is taken to be zero
for vaccinated individuals. We also consider two other values of τ to ensure consistency
of the obtained results (see Fig. 7). It is observed that vaccination not only reduces the
viral load in healthy patients but also reduces the duration of high viremia.
Overall, for antiviral drug target, blocking virus production is more fruitful in terms
of viral load reduction and vaccination will also be effective.
6. Discussion and conclusion
In this study, we have proposed and analyzed a compartmental model of SARS-CoV-
2 transmission within the human body. The much needed innate and adaptive immune
responses are incorporated into the model. The seven-dimensional model has four types of
equilibrium points. The existence criterion for each type of equilibria is presented. From
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Figure 6: Effect of antiviral drugs that (a) reduce infection or (b) blocks virus production. The time
series of viral load is presented for different values of ǫ1 and ǫ2. The fixed parameters are taken from
Table 1 with µ2 = 0.65, k2 = 5, η = 0.05 and τ = 7. Other fixed values are taken to be the average of
estimated parameters for patient A and patient B.
the local stability of the DFE, the expression for basic reproduction number is obtained.
This number is very crucial for the persistence of the virus in the long run. However,
the short-term dynamics of the viral load is studied using various numerical techniques.
During time series analysis, we observed that the viral load time series experiences a
peak between sixth and seven days post-infection, followed by a sharp decrease due to
activation of adaptive immune response (see Fig. 2). A forward bifurcation of equilibria
with respect to the basic reproduction number is observed and depicted in Fig. 3. This
also ensures that if we suitably vary parameters involved in the expression of R0, the
same type of phenomenon occurs. Thus, in turn, parameters such as β and k1 can be
decreased to reduce R0 below unity and ensure local asymptotic stability of DFE.
We used daily measurements of SARS-CoV-2 viral load in sputum for two patients
[31] from a hospital in Munich, Germany. Using the estimated parameters, the global
sensitivity analysis of several model parameters with respect to peak viral load is per-
formed. The results indicate that the production rate of virus particles from infected cells
will increase the chance of more significant infection propagation. Besides, the infection
rate and the immiunosuppresion rate will increase the peak of viral load. Additionally,
the natural death rates of infected cells and the death rate of virus particles will have
a significant negative correlation with the peak of viral load. The production rate of
cytokines is also negatively correlated with the peak of viral load. These results reinforce
the fact that β and k1 are very crucial for the reduction of viral load.
Antiviral drugs can be used to slow SARS-CoV-2 infection (or reduce β) or block the
production of virus particles (or reduce k1). These drugs will necessarily save the lives
of many severely ill patients and will reduce the time spent in intensive care units for
patients, vacating hospital beds. Antiviral medications will, in turn, inhibit subsequent
transmission that could happen if the drugs were not given. World Health Organization
(WHO) is focusing on the following four therapies: an experimental antiviral compound
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Figure 7: Viral load time series for different values of τ for the model (2.1). The fixed parameters are
taken from Table 1 with µ2 = 0.65, k2 = 5, η = 0.05 and τ = 7. Other fixed values are taken to be the
average of estimated parameters for patient A and patient B.
called remdesivir; the malaria medications chloroquine and hydroxychloroquine; a com-
bination of two HIV drugs, lopinavir and ritonavir; and that same combination plus
interferon-beta, an immune system messenger that can help cripple viruses [36]. Results
suggest that a decrease in β reduces the peak of viral load but the duration of the high
viral load remains the same. On the other hand, a decrease in k1 significantly reduce both
peak of viral load and period of high viral load. Thus, we conclude that blocking virus
production from infected cells is a more suitable target for antiviral drug development.
Moreover, vaccination can reduce the viral load in healthy patients and also reduce the
duration of high viremia in the body. But vaccine development is a complicated task;
therefore, during the vaccine development phase, blocking virus production from infected
cells can be targeted for antiviral drug development.
Researchers have been putting more effort to develop a vaccine to tackle COVID-
19 [9, 10]. The journey has started with the first clinical trial just two months after
the genetic sequence of the virus. The mathematical model developed in this paper
can be improved by adding more detailed data to reveal prophylactic and therapeutic
interventions. Our theoretical findings should be tested clinically for the implementation.
Further insights into immunology and pathogenesis of SARS-CoV-2 will help to improve
the outcome of this and future pandemics.
14
References
[1] Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu,
Li Zhang, Guohui Fan, Jiuyang Xu, Xiaoying Gu, et al. Clinical features of patients
infected with 2019 novel coronavirus in wuhan, china. The Lancet, 395(10223):497–
506, 2020.
[2] Abba B Gumel, Shigui Ruan, Troy Day, James Watmough, Fred Brauer, P Van den
Driessche, Dave Gabrielson, Chris Bowman, Murray E Alexander, Sten Ardal, et al.
Modelling strategies for controlling sars outbreaks. Proceedings of the Royal Society
of London. Series B: Biological Sciences, 271(1554):2223–2232, 2004.
[3] Wenhui Li, Michael J Moore, Natalya Vasilieva, Jianhua Sui, Swee Kee Wong,
Michael A Berne, Mohan Somasundaran, John L Sullivan, Katherine Luzuriaga,
Thomas C Greenough, et al. Angiotensin-converting enzyme 2 is a functional recep-
tor for the sars coronavirus. Nature, 426(6965):450–454, 2003.
[4] Raoul J de Groot, Susan C Baker, Ralph S Baric, Caroline S Brown, Christian
Drosten, Luis Enjuanes, Ron AM Fouchier, Monica Galiano, Alexander E Gor-
balenya, Ziad A Memish, et al. Commentary: Middle east respiratory syndrome
coronavirus (mers-cov): announcement of the coronavirus study group. Journal of
virology, 87(14):7790–7792, 2013.
[5] Emmie de Wit, Neeltje van Doremalen, Darryl Falzarano, and Vincent J Munster.
Sars and mers: recent insights into emerging coronaviruses. Nature Reviews Micro-
biology, 14(8):523, 2016.
[6] Benjamin J Cowling, Minah Park, Vicky J Fang, Peng Wu, Gabriel M Leung, and
Joseph T Wu. Preliminary epidemiologic assessment of mers-cov outbreak in south
korea, may–june 2015. Euro surveillance: bulletin Europeen sur les maladies trans-
missibles= European communicable disease bulletin, 20(25), 2015.
[7] KH Kim, TE Tandi, Jae Wook Choi, JM Moon, and MS Kim. Middle east respi-
ratory syndrome coronavirus (mers-cov) outbreak in south korea, 2015: epidemiol-
ogy, characteristics and public health implications. Journal of Hospital Infection,
95(2):207–213, 2017.
[8] Kin On Kwok, Arthur Tang, Vivian WI Wei, Woo Hyun Park, Eng Kiong Yeoh, and
Steven Riley. Epidemic models of contact tracing: Systematic review of transmission
studies of severe acute respiratory syndrome and middle east respiratory syndrome.
Computational and structural biotechnology journal, 2019.
15
[9] Kuldeep Dhama, Khan Sharun, Ruchi Tiwari, Maryam Dadar, Yashpal Singh Malik,
Karam Pal Singh, and Wanpen Chaicumpa. Covid-19, an emerging coronavirus in-
fection: advances and prospects in designing and developing vaccines, immunother-
apeutics, and therapeutics. Human Vaccines & Immunotherapeutics, pages 1–7,
2020.
[10] Nicole Lurie, Melanie Saville, Richard Hatchett, and Jane Halton. Developing covid-
19 vaccines at pandemic speed. New England Journal of Medicine, 2020.
[11] Vineet D Menachery, Boyd L Yount Jr, Kari Debbink, Sudhakar Agnihothram,
Lisa E Gralinski, Jessica A Plante, Rachel L Graham, Trevor Scobey, Xing-Yi Ge,
Eric F Donaldson, et al. A sars-like cluster of circulating bat coronaviruses shows
potential for human emergence. Nature medicine, 21(12):1508, 2015.
[12] Esteban Abelardo Hernandez Vargas and Jorge X Velasco-Hernandez. In-host mod-
elling of covid-19 kinetics in humans. medRxiv, 2020.
[13] Tony Y Hu, Matthew Frieman, and Joy Wolfram. Insights from nanomedicine into
chloroquine efficacy against covid-19. Nature Nanotechnology, 15(4):247–249, 2020.
[14] Ahmed Yaqinuddin and Junaid Kashir. Innate immunity in covid-19 patients medi-
ated by nkg2a receptors, and potential treatment using monalizumab, cholroquine,
and antiviral agents. Medical Hypotheses, page 109777, 2020.
[15] Matthew Zirui Tay, Chek Meng Poh, Laurent Re´nia, Paul A MacAry, and Lisa FP
Ng. The trinity of covid-19: immunity, inflammation and intervention. Nature
Reviews Immunology, pages 1–12, 2020.
[16] Joseph T Wu, Kathy Leung, and Gabriel M Leung. Nowcasting and forecasting the
potential domestic and international spread of the 2019-ncov outbreak originating
in wuhan, china: a modelling study. The Lancet, 395(10225):689–697, 2020.
[17] Biao Tang, Nicola Luigi Bragazzi, Qian Li, Sanyi Tang, Yanni Xiao, and Jianhong
Wu. An updated estimation of the risk of transmission of the novel coronavirus
(2019-ncov). Infectious Disease Modelling, 2020.
[18] Adam J Kucharski, Timothy W Russell, Charlie Diamond, Yang Liu, John Ed-
munds, Sebastian Funk, Rosalind M Eggo, Fiona Sun, Mark Jit, James D Munday,
et al. Early dynamics of transmission and control of covid-19: a mathematical
modelling study. The lancet infectious diseases, 2020.
16
[19] Marek Kochan´czyk, Frederic Grabowski, and Tomasz Lipniacki. Dynamics of covid-
19 pandemic at constant and time-dependent contact rates. Mathematical Modelling
of Natural Phenomena, 15:28, 2020.
[20] Sean Quan Du and Weiming Yuan. Mathematical modeling of interaction between
innate and adaptive immune responses in covid-19 and implications for viral patho-
genesis. Journal of Medical Virology, 2020.
[21] Abdurrahman Tufan, ASLIHAN AVANOG˘LU GU¨LER, and Marco Matucci-
Cerinic. Covid-19, immune system response, hyperinflammation and repurposing
antirheumatic drugs. Turkish Journal of Medical Sciences, 50(SI-1):620–632, 2020.
[22] Julia L McKechnie and Catherine A Blish. The innate immune system: fighting on
the front lines or fanning the flames of covid-19? Cell Host & Microbe, 2020.
[23] Stanca M Ciupe and Jane M Heffernan. In-host modeling. Infectious Disease Mod-
elling, 2(2):188–202, 2017.
[24] Sourav Kumar Sasmal, Yueping Dong, and Yasuhiro Takeuchi. Mathematical mod-
eling on t-cell mediated adaptive immunity in primary dengue infections. Journal
of theoretical biology, 429:229–240, 2017.
[25] Didier Raoult, Alimuddin Zumla, Franco Locatelli, Giuseppe Ippolito, and Guido
Kroemer. Coronavirus infections: Epidemiological, clinical and immunological fea-
tures and hypotheses. Cell Stress, 4(4):66, 2020.
[26] AC Fowler. Approximate solution of a model of biological immune responses incor-
porating delay. Journal of mathematical biology, 13(1):23–45, 1981.
[27] Tanvi P Gujarati and G Ambika. Virus antibody dynamics in primary and secondary
dengue infections. Journal of mathematical biology, 69(6-7):1773–1800, 2014.
[28] Ryan Nikin-Beers and Stanca M Ciupe. The role of antibody in enhancing dengue
virus infection. Mathematical biosciences, 263:83–92, 2015.
[29] Hannah E Clapham, Vianney Tricou, Nguyen Van Vinh Chau, Cameron P Simmons,
and Neil M Ferguson. Within-host viral dynamics of dengue serotype 1 infection.
Journal of the Royal Society Interface, 11(96):20140094, 2014.
[30] WHO. ”immunity passports” in the context of covid-19.
https://www.who.int/news-room/commentaries/detail/immunity-passports-in-the-context-of-covid-19.
Retrieved : 2020-05-26.
17
[31] Roman Wo¨lfel, Victor M Corman, Wolfgang Guggemos, Michael Seilmaier, Sabine
Zange, Marcel A Mu¨ller, Daniela Niemeyer, Terry C Jones, Patrick Vollmar, Camilla
Rothe, et al. Virological assessment of hospitalized patients with covid-2019. Nature,
pages 1–5, 2020.
[32] WPD. Online software for data extraction. https://apps.automeris.io/wpd/.
Retrieved : 2020-05-20.
[33] Simeone Marino, Ian B Hogue, Christian J Ray, and Denise E Kirschner. A method-
ology for performing global uncertainty and sensitivity analysis in systems biology.
Journal of theoretical biology, 254(1):178–196, 2008.
[34] Jose´ Antonio Encinar and Javier A Menendez. Potential drugs targeting early innate
immune evasion of sars-coronavirus 2 via 2-o-methylation of viral rna. Viruses,
12(5):525, 2020.
[35] Leon Caly, Julian D Druce, Mike G Catton, David A Jans, and Kylie M Wagstaff.
The fda-approved drug ivermectin inhibits the replication of sars-cov-2 in vitro.
Antiviral research, page 104787, 2020.
[36] Kai Kupferschmidt and Jon Cohen. Who launches global megatrial of the four most
promising coronavirus treatments. Science, 22, 2020.
[37] Carolin Zitzmann and Lars Kaderali. Mathematical analysis of viral replication
dynamics and antiviral treatment strategies: from basic models to age-based multi-
scale modeling. Frontiers in microbiology, 9:1546, 2018.
18
